News
SurvivorNet on MSN4h
A Promising New Option For PIK3CA-Mutated Breast Cancer: What New Data On Inavolisib Could Mean for YouInavolisib (Itovebi) is a new targeted therapy for HR+ HER2-negative metastatic breast cancer with a PIK3CA mutation.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback